Advanced Breast Cancer: ARV-471 vs Fulvestrant

We are studying a new medication, ARV-471, to see if it works better than fulvestrant for patients with advanced estrogen receptor-positive, HER2-negative breast cancer. This trial is for those whose cancer has progressed after prior treatments.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Fulvestrant Ever Pharma
Fulvestrant Ever Pharma is a medicine used to treat certain breast cancers in postmenopausal women that have spread or come back.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Fulvestrant
Fulvestrant blocks and destroys estrogen receptors to treat hormone receptor–positive breast cancer.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Pf-07850327

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Afultrant
Ambiful
Falvax

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
University Hospital Graz
LKH-Univ., Klinikum Graz, University clinic for gynecology and obstetrics
Graz, Austria
Klinikum Klagenfurt Am Woerthersee
Hematology and Oncology
Klagenfurt am Wörthersee, Austria
LKH Hochsteiermark - Standort Leoben
division for internal medicine, dept. hemato-oncology
Leoben, Austria

Sponsor: Pfizer Inc.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.